Theidel, Ulrike; von der Schulenburg, Johann-Matthias Graf - In: Health Economics Review 6 (2016) 33, pp. 1-12
Background: The AMNOG regulation, introduced in 2011 in Germany, changed the game for new drugs. Now, the industry is required to submit a dossier to the GBA (the central decision body in the German sickness fund system) to show additional benefit. After granting the magnitude of the additional...